Clinical Trends for July 2018

Ryan Syrek


July 27, 2018

Each week, we identify one top search term, speculate as to what caused its popularity, and provide an infographic on a related condition. If you have thoughts about what's trending and why, feel free to share them with us on Twitter or Facebook!

Trending Clinical Topic of the Week (July 21-27): Migraine

An important association and several new findings about treatment and prevention options for migraine, as presented at the American Headache Society (AHS) Annual Meeting, led to the increased popularity in this week's top search term. Initially, study results indicating an association between chronic migraine and cognitive impairment were reported at the meeting. Unlike previous research, which had indicated a potential role for the anticonvulsant topiramate as well as a possible role for depressive disorder, anxiety disorder, and nonreparative sleep in cognitive impairment, migraine was the only relevant factor in this study associated with worse performance.

A separate study presented at the meeting found that the oral calcitonin gene-related peptide (CGRP) rimegepant performed well compared with placebo in a phase 3 trial in treating a single, acute migraine attack. Freedom from pain was reported by 20% of participants in the active treatment group 2 hours after dosing, compared with 12% of the placebo group. Treatment of photophobia was even more pronounced, with 38% of those receiving rimegepant reporting relief, compared with 25% of the placebo group.

Another presentation at the meeting reported findings suggesting that the CGRP antagonist fremanezumab is associated with increased efficacy, better tolerance, and greater functional improvement in the prevention of chronic migraine when compared with topiramate. Topiramate was also found to be inferior to use of onabotulinumtoxinA in the prevention of chronic migraine in a separate head-to-head, prospective, open-label study. The AHS Annual Meeting clearly provided plenty of material that resulted in migraine becoming this week's top search term.

For more information on migraine headache, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.